Exchange: NASDAQ·Updated 07:55 PM EST

AYTU News

News
all
press releases
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Aytu BioPharma, Inc. (NASDAQ: AYTU)
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Aytu BioPharma, Inc. (NASDAQ: AYTU) $HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Aytu BioPharma, Inc. (NASDAQ: AYTU)PR NewswireNEW YORK, Nov. 18, 2026 NEW YORK, Nov. 18, 2026 /PRNewswire...
PR Newswire
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Aytu BioPharma, Inc. (NASDAQ: AYTU)
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Aytu BioPharma, Inc. (NASDAQ: AYTU) $HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Aytu BioPharma, Inc. (NASDAQ: AYTU)PR NewswireNEW YORK, Nov. 18, 2026 NEW YORK, Nov. 18, 2026 /PRNewswire...
PR Newswire
More News
Are GLND, RPID, AYTU Obtaining Fair Deals for their Shareholders? Are GLND, RPID, AYTU Obtaining Fair Deals for their Shareholders?PR NewswireNEW YORK, Nov. 18, 2026 Insiders may stand to receive substantial financial benefits not available to ordinary shareholders. The proposed transactions may...
PR Newswire
Aytu BioPharma (NASDAQ:AYTU) agreed to a $2.70-per-share cash acquisition by UK-based Rosemont Pharmaceuticals, giving shareholders a substantial premium while providing Rosemont with an established US specialty pharmaceutical platform.
24-7 Market News
Aytu Biopharma surged 42.9% after strong revenue and a proposed Rosemont acquisition; Cloudastructure led gainers, while Bridger Aerospace and Stem fell.read more...
Benzinga
Aytu BioPharma shares surged after hours as investors assessed results and acquisition terms.read more...
Benzinga
Halper Sadeh LLC, an investor rights law firm, is investigating the sale of Aytu BioPharma, Inc. (NASDAQ: AYTU) to Rosemont Pharmaceuticals Holdings, Inc. for $2.70 per share.Halper Sadeh encourages Aytu shareholders to click here to learn more about their rights and options or contact Daniel Sadeh...
Business Wire
Aytu BioPharma, Inc. (AYTU) delivered earnings and revenue surprises of -100.00% and +2.36%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Cerenome (CNSY) delivered earnings and revenue surprises of -16.33% and +44.40%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Zealand Pharma AS (ZLDPF) delivered earnings and revenue surprises of +90.98% and -97.57%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
CytomX Therapeutics (CTMX) delivered earnings and revenue surprises of 0.00% and -59.68%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks

Advertisement|Remove ads.